ArticleBioscience reports2013
The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma.
Article in Bioscience reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Gnao1 acts as a gatekeeper to alleviate neuropathic pain by silencing pro-nociceptive signaling cascades.The journal of headache and pain · 2026Article
- Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.Molecular therapy. Nucleic acids · 2025Article
- CircGNAO1 strengthens its host gene GNAO1 expression for suppression of hepatocarcinogenesis.Heliyon · 2024Article
- Construction of a ceRNA network to reveal a vascular invasion associated prognostic model in hepatocellular carcinoma.Open medicine (Warsaw, Poland) · 2023Article
- Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology.PLoS neglected tropical diseases · 2022Article
- Emerging role of different DNA methyltransferases in the pathogenesis of cancer.Frontiers in pharmacology · 2022Review
- GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.Journal of healthcare engineering · 2021Article
- Genome-Wide Methylation Profiling in Canine Mammary Tumor Reveals miRNA Candidates Associated with Human Breast Cancer.Cancers · 2019Article
- MicroRNA-550a is associated with muscle system conferring poorer survival for esophageal cancer.Bioscience reports · 2019Article
- Identification of Sex-Specific Transcriptome Responses to Polychlorinated Biphenyls (PCBs).Scientific reports · 2019Article
- Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis.Medicine · 2017Article
- Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.World journal of surgical oncology · 2017Article
- Bioinformatic Prediction of Possible Targets and Mechanisms of Action of the Green Tea Compound Epigallocatechin-3-Gallate Against Breast Cancer.Frontiers in molecular biosciences · 2017Article
- Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma.PloS one · 2017Article
- Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach.Radiology and oncology · 2014Article
- Clinical Phenotype of De NovoChild neurology openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GNAO1 (guanine nucleotide-binding protein, α-activating activity polypeptide O) is a member of the subunit family of Gα proteins, which are molecular switchers controlling signal transductions and whose deregulation can promote oncogenesis. HCC (hepatocellular carcinoma) is one of the malignant tumours around the world, which summons novel biomarkers or targets for effective diagnosis and treatments. The present study was aimed to investigate the expression of GNAO1 in HCC patient tissues and the possible mechanisms by which it took effects. The expression of GNAO1 was detected by IHC (immunohistochemistry) and real-time qPCR (quantitative PCR). Cell proliferation test and cell senescence test were then performed to explore the role of GNAO1 in the occurrence and development of HCC. It was revealed that the level of GNAO1 was comparably less in HCC tissues than in the adjacent tissues. Furthermore, down-regulation of GNAO1 increased cell proliferation, while suppressing the senescence of HCC cells. In conclusion, our findings revealed and confirmed the importance of GNAO1 in HCC, indicating that GNAO1 is a potential biomarker as well as a promising therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.